Association of Elevated Serum Lipoprotein(a), Inflammation, Oxidative Stress and Chronic Kidney Disease with Hypertension in Non-diabetes Hypertensive Patients

[1]  B. Goswami,et al.  Lipoprotein(a), ferritin, and albumin in acute phase reaction predicts severity and mortality of acute ischemic stroke in North Indian Patients. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[2]  L. Pfeffer,et al.  Mitochondria Control Functional CaV1.2 Expression in Smooth Muscle Cells of Cerebral Arteries , 2010, Circulation research.

[3]  S. Im,et al.  Cinnamon extract induces tumor cell death through inhibition of NFκB and AP1 , 2010, BMC Cancer.

[4]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[5]  M. Cavasin,et al.  Role of Inflammation in the Development of Renal Damage and Dysfunction in Angiotensin II–Induced Hypertension , 2008, Hypertension.

[6]  G. Lip,et al.  Oxidative stress and hypertension , 2006, International journal of clinical practice.

[7]  H. Björkbacka.  Multiple roles of Toll-like receptor signaling in atherosclerosis , 2006, Current opinion in lipidology.

[8]  L. Sechi,et al.  New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a) , 2005, Journal of hypertension.

[9]  L. Kuller,et al.  Lipoprotein Levels Are Associated with Incident Hypertension in Older Adults , 2004, Journal of the American Geriatrics Society.

[10]  A. Scanu.  Lipoprotein(a) and the atherothrombotic process: Mechanistic insights and clinical implications , 2003, Current atherosclerosis reports.

[11]  G. Lippi,et al.  Lipoprotein(a): An Emerging Cardiovascular Risk Factor , 2003, Critical reviews in clinical laboratory sciences.

[12]  J. Morrow,et al.  Factors associated with oxidative stress in human populations. , 2002, American journal of epidemiology.

[13]  C. Catena,et al.  Lipoprotein (a), haemostatic variables and cardiovascular damage in hypertensive patients , 2000, Journal of hypertension.

[14]  A. Levey,et al.  The role of systemic hypertension in the progression of nondiabetic renal disease. , 2000, Kidney international. Supplement.

[15]  C. Catena,et al.  Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. , 1999, Kidney international.

[16]  P. Whelton,et al.  Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[17]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[18]  G. Lippi,et al.  Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response. , 1998, Clinica chimica acta; international journal of clinical chemistry.

[19]  F. Colombo,et al.  Lp(a) in hypertensive patients , 1998, Journal of Human Hypertension.

[20]  C. Wanner,et al.  Lipoprotein(a) induces glomerular superoxide anion production. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  C. Gazzaruso,et al.  Lipoprotein(a) Plasma Concentrations, Apolipoprotein (a) Polymorphism and Family History of Coronary Heart Disease in Patients with Essential Hypertension , 1996, Journal of cardiovascular risk.

[22]  T. Meyer,et al.  Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. , 1995, The Journal of clinical investigation.

[23]  C. Hamm,et al.  Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a) , 1995, Circulation.

[24]  Lippincott Williams Wilkins,et al.  1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. , 1993, Hypertension.

[25]  K. Walton,et al.  A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. , 1974, Atherosclerosis.

[26]  S. Tangvarasittichai.  Serum levels of malondialdehyde in type 2 diabetes mellitus Thai subjects. , 2009 .

[27]  M. Simionescu,et al.  Vascular endothelium in atherosclerosis , 2008, Cell and Tissue Research.

[28]  N. Rifai,et al.  C-reactive protein: a nontraditional serum marker of cardiovascular risk. , 2007, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[29]  Bruce Neal,et al.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. , 1999, Journal of hypertension.

[30]  R. D'Agostino,et al.  Clinical correlates of hypertensive end-stage renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  Detection.  The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[32]  J. Davignon,et al.  Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a). , 1994, Chemistry and physics of lipids.